Exhibit 99.3

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

The following unaudited pro forma condensed combined financial statements of PRA Health Sciences, Inc. (“PRA” or the “Company”) present the combination of the historical financial information of the Company and Symphony Health Solutions Corporation (“Symphony Health”) adjusted to give effect to the acquisition, as described in “Description of the Acquisition” in the notes to the unaudited pro forma condensed combined financial statements, to be accounted for under the acquisition method of accounting in accordance with Accounting Standards Codification 805, Business Combinations (“ASC 805”).

The Unaudited Pro Forma Condensed Combined Balance Sheet is presented as if the acquisition had occurred on June 30, 2017. The Unaudited Pro Forma Condensed Combined Statements of Operations for the six months ended June 30, 2017 and the year ended December 31, 2016 are presented as if the acquisition had occurred on January 1, 2016, the beginning of the earliest period presented. The unaudited pro forma financial information is based on the historical consolidated financial statements of PRA and Symphony Health, and the assumptions and adjustments set forth in the accompanying explanatory notes.

These unaudited pro forma combined financial information and the accompanying notes should be read together with (1) the Company’s audited consolidated financial statements and accompanying notes, as of and for the year ended December 31, 2016, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on February 23, 2017, (2) the Company’s unaudited consolidated financial statements and accompanying notes as of and for the six months ended June 30, 2017 and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, which was filed with the SEC on August 8, 2017, (3) Symphony Health’s audited consolidated financial statements for the year ended December 31, 2016, included as exhibit 99.1 to this Form 8-K/A, and (4) Symphony Health’s unaudited consolidated financial statements as of and for the six months ended June 30, 2017, included as exhibit 99.2 to this Form 8-K/A.

For purposes of developing the Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2017, the acquired Symphony Health assets, including identifiable intangible assets, and liabilities assumed have been recorded at their estimated fair values with the excess purchase price assigned to goodwill. The estimated fair values assigned in this unaudited pro forma financial information are preliminary and represent PRA’s current best estimate of fair value and are subject to revision. The unaudited pro forma financial information is provided for informational purposes only and is based on available information and assumptions that PRA believes are reasonable. It does not purport to represent what the actual consolidated results of operations or the consolidated financial position of PRA would have been had the acquisition occurred on the dates indicated, nor is it necessarily indicative of future consolidated results of operations or consolidated financial position. The actual financial position and results of operations will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified and changes in operating results following the date of the pro forma financial information.

The actual operating results for Symphony Health will be consolidated with the Company’s operating results for all periods subsequent to the acquisition date of September 6, 2017.

1

Unaudited Pro Forma Condensed Combined Balance Sheet

As of June 30, 2017

(in thousands)

See accompanying notes to unaudited pro forma condensed combined financial information.

2

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Six Months Ended June 30, 2017

(in thousands, except per share data)

See accompanying notes to unaudited pro forma condensed combined financial information.

3

Unaudited Pro Forma Condensed Combined Statement of Operations

For the Year Ended December 31, 2016

(in thousands, except per share data)

See accompanying notes to unaudited pro forma condensed combined financial information.

4

Notes to Unaudited Pro Forma Condensed Combined Financial Information

1. Description of the Acquisition

On September 6, 2017, Pharmaceutical Research Associates, Inc. (“PRA, Inc.”), a Virginia corporation and a wholly-owned subsidiary of PRA Health Sciences, Inc. (“PRA” or the “Company”), completed the previously announced acquisition (the “Acquisition”) of Symphony Health Solutions Corporation (“Symphony Health”), pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 3, 2017, by and among PRA, Inc., Symphony Health, Skyhook Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of PRA, Inc. (“Merger Sub”), and STG III, L.P., a Delaware limited partnership, solely in its capacity as the representative (the “Sellers Representative”) of holders of Symphony Health’s capital stock and stock options. Pursuant to the Merger Agreement, Merger Sub merged with and into Symphony Health on September 6, 2017 (the “Merger”), with Symphony Health continuing as the surviving corporation and a wholly-owned subsidiary of PRA, Inc.

Pursuant to the Merger Agreement, PRA, Inc. paid approximately $540.8 million in cash for the outstanding equity of Symphony Health, which is subject to customary post-closing adjustments. Under the Merger Agreement, PRA, Inc. may be required to make additional payments in the form of contingent consideration, which is not capped, to the prior equity holders of Symphony Health pursuant to an earnout provision that is based on Symphony Health exceeding financial targets for the twelve month periods ending December 2017 and December 2018.

2. Financing Transaction

The Company funded the cash consideration for the Merger with proceeds from borrowings under the Joinder (as defined below). PRA, Inc., certain domestic subsidiaries of PRA, Inc., as grantors and guarantors, the lenders party thereto and Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent and collateral agent, entered into the Joinder Agreement (the “Joinder”) on September 6, 2017, which amended the Credit Agreement, dated as of December 6, 2016 (the “Credit Agreement” and, as amended by the Joinder, the “Amended Credit Agreement”), by and among the Company, PRA, Inc., as the borrower, each lender from time to time party thereto and Wells Fargo, as administrative agent, collateral agent, letter of credit issuer and swingline lender. Pursuant to the terms of the Joinder, PRA, Inc. exercised its right under the Credit Agreement to establish an additional tranche of term loans (the “New Term Loan”), pursuant to which, on September 6, 2017, PRA, Inc. borrowed an aggregate principal amount of $550 million to be used to finance the Merger and for general corporate purposes.

The New Term Loan matures on December 6, 2021 and bears interest at a rate equal to LIBOR or the adjusted base rate (“ABR”), plus a margin based on the ratio of total indebtedness to EBITDA, ranging from 1.25% to 2.00%, in the case of LIBOR rate loans, and 0.25% to 1.00%, in the case of ABR rate loans. Under the terms of the Joinder, the New Term Loan will amortize in equal quarterly installments of an aggregate annual amount equal to 2.5% of the original principal amount of the New Term Loan, with any remaining balance payable at maturity. Other than with respect to the applicable interest rate and amortization schedule, all terms and conditions applicable to the New Term Loan, including provisions governing mandatory and voluntary prepayments, affirmative and negative covenants and events of default and related penalties, are substantially the same as the terms and conditions contained in the Credit Agreement, as previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on December 6, 2016.

3. Basis of Presentation

The accompanying unaudited pro forma condensed combined financial statements give effect to the acquisition of Symphony Health by PRA.  The unaudited pro forma financial information is based on the historical consolidated financial statements of PRA and Symphony Health, and the assumptions and adjustments set forth in

5

these notes. The unaudited pro forma financial information is provided for informational purposes only and is based on available information and assumptions that the Company believes are reasonable. It does not purport to represent what the actual consolidated results of operations or the consolidated financial position of the Company would have been had the acquisition occurred on the dates indicated, nor is it necessarily indicative of future consolidated results of operations or consolidated financial position. The actual financial position and results of operations will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified and changes in operating results following the date of the pro forma financial information.

Pro forma adjustments are included only to the extent they are (i) directly attributable to the acquisition, (ii) factually supportable and (iii) with respect to the statements of operations, expected to have a continuing impact on the combined results. The accompanying unaudited pro forma condensed combined financial information is presented for informational purposes only and is based on available information and assumptions that the Company believes are reasonable.

The unaudited pro forma condensed combined financial information does not reflect any cost savings from operating efficiencies or revenue synergies that could result from the acquisition.

The acquisition will be accounted for using the acquisition method of accounting. The unaudited pro forma financial information reflects the preliminary assessment of fair values and useful lives assigned to the assets acquired and liabilities assumed. Fair value estimates were determined based on preliminary discussions between the Company and Symphony Health, due diligence efforts and publicly disclosed information for other business combinations in the industry.  The detailed valuation studies necessary to arrive at the required estimates of the fair values for the Symphony Health assets acquired and liabilities assumed have not been completed. Significant assets and liabilities that are subject to preparation of valuation studies to determine appropriate fair value adjustments include fixed assets, identifiable intangible assets, and advanced billings. Changes to the fair values of these assets and liabilities will also result in changes to goodwill and deferred income tax liabilities, which could be material.

The Unaudited Pro Forma Condensed Combined Balance Sheet is presented as if the acquisition had occurred on June 30, 2017. The Unaudited Pro Forma Condensed Combined Statements of Operations for the six months ended June 30, 2017 and the year ended December 31, 2016 are presented as if the acquisition had occurred on January 1, 2016, the beginning of the earliest period presented.

4. Preliminary Purchase Consideration

The fair value of the acquisition consideration, or the purchase price, in the unaudited pro forma financial information as if the acquisition date was June 30, 2017 is estimated to be approximately $650.2 million.  The purchase price includes $541.4 million in cash paid at close and the initial estimate of the earnout liability totaling $108.8 million.

The following table presents the preliminary allocation of purchase price to the assets to be acquired and liabilities to be assumed in the merger (in thousands):

6

Upon completion of the fair value assessment following the acquisition, PRA anticipates the finalized fair values of the net assets acquired will differ from the preliminary assessment outlined above. Generally, changes to the initial estimates of the fair value of the assets acquired and liabilities assumed within a one-year measurement period from the acquisition date will be recorded as adjustments to those assets and liabilities and residual amounts will be allocated to goodwill, which could be material.

5. Acquisition-Related Pro Forma Adjustments

The unaudited pro forma financial information reflects the following adjustments related to the merger:

(a)         Cash and cash equivalents. Adjustment reflects the preliminary net adjustment to cash in connection the Acquisition:

(b)         Other current assets.  Adjustment reflects the current portion of prepaid representations and warranties insurance purchased in connection with the Acquisition.

(c)          Goodwill. Adjustment to record goodwill resulting from the acquisition of Symphony Health. Goodwill represents the residual of the purchase price over the fair value of the identified assets acquired and liabilities assumed. Goodwill is not amortized but evaluated for impairment annually, or more frequently if events or changes in circumstances indicate an impairment.

(d)         Intangible assets. Adjustment reflect the estimated fair values of Symphony Health’s identifiable intangible assets. The primary assets include customer relationships, software, databases, and the Symphony Health trade name.

The following tables summarizes information about the other identifiable intangible assets (in thousands, except useful life information):

For the six months ended June 30, 2017, incremental amortization expense on the above intangible assets was $12.4 million. For the year ended December 31, 2016, incremental amortization expense on the above intangible assets was $24.9 million.

(e)          Other Assets.  Adjustment reflects the noncurrent portion of prepaid representations and warranties insurance totaling $0.5 million purchased in connection with the Acquisition offset by the reclass of deferred tax assets totaling $21.7 million which were netted against deferred tax liabilities associated with identified intangibles.  See Note 5(j) for further information.

7

(f)           Long-term debt.  Adjustment reflects a net increase in long-term debt related to financing transaction discussed in Note 2 as follows:

(g)          Accrued expenses and other current liabilities.  Adjustment reflects the current portion of earnout liability (discussed in Note 4) totaling $90.4 million offset by the write-off of $0.3 million accrued interest associated with Symphony Health’s debt.

(h)         Advanced billings.  Adjustment of $1.3 million to reflect the fair value of the assumed performance obligations of Symphony Health using a cost build-up approach.  The revenue associated with this downward adjustment will not be recognized by the combined company post-acquisition.

(i)             Other long-term liabilities.  The preliminary pro forma adjustment is calculated as follow:

(j)            Deferred taxes.  Adjustment reflects the deferred income tax effects of the preliminary pro forma adjustments made to the pro forma balance sheet, using the U.S statutory tax rate of 35.0% and a blended state tax rate of 4.5% primarily as indicated in the table below:

8

(k)         Stockholders’ equity. Adjustment to eliminate all Symphony Health’s stockholders’ equity, including preferred stock, common stock, additional paid-in capital, and accumulated deficit. Transaction costs and the loss on modification of debt totaling $9.3 million, net of a $3.7 million deferred tax benefit were adjusted to retained earnings.

(l)             Acquisition-related costs.  Adjustment to remove $1.0 million of acquisition-related costs that were recorded in the Company’s and Symphony Health’s historical results for the six months ended June 30, 2017.

(m)     Interest Expense.  Reflects the adjustment to interest expense associated with the New Term Loan and the payoff of Symphony’s Health’s outstanding indebtedness.  The pro forma adjustment for interest expense for the six months ended June 30, 2017 and the year ended December 31, 2016 is as follows:

(n)         Provision for (benefit from) income taxes.  Adjustment reflects the income tax effect of the pro forma adjustments made to the pro forma condensed combined statements of operations using the U.S. federal statutory tax rate of 35.0% and a blended state tax rate of 4.5%.

9